DarioHealth Corp. (DRIO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
DarioHealth Corp. (DRIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 3, 2026, on the recommendation of the Nominating Committee of the Board of Directors, or the Board, of DarioHea
- Person
- John R. Palumbo
- Title
- Chairman of the Board
- Action
- appointed
- Effective
- effective immediately
- Predecessor
- Yoav Shaked
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The appointment is a routine corporate governance update with limited immediate price impact.
Market read
A standard SEC filing reporting a director change; low trading relevance.
What to watch
Potential hidden strategic initiatives behind the new chairman appointment are not disclosed.
Background
DarioHealth Corp filed a Form 8‑K on Nov 6, 2026, announcing a board leadership change.
Ticker impact
SEC Form 8‑K reports appointment of John R. Palumbo as Chairman, replacing Yoav Shaked.
likely limited pressure as market prices in the appointment.
Director appointments are routine corporate actions with modest short‑term effect; no financial terms disclosed.
Market effects
Minimal impact on the digital health sector; governance change does not alter competitive dynamics.
US OTC market only; no broader regional effect.
Low; the filing is company‑specific without macro implications.
Counterpoint
If investors view the leadership change as a signal of strategic shift, the stock could see upside.
Key entities
- personJohn R. Palumbo
Appointed Chairman of the Board
- personYoav Shaked
Former Chairman, remains board member
